Paola Andrea Barroso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paola Andrea Barroso has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Jorge Diego Marco
Instituto de Patología Experimental, Universidad Nacional de Salta, Av. Bolivia 5150, C.P. 4400, Salta, Argentina
3 shared publications - Aldana Malen Corlatti
CONICET-Universidad de Buenos Aires, Instituto de Química y Metabolismo del Fármaco (IQUIMEFA), Buenos Aires C1113AAD, Argentina
2 shared publications - Dolores Catalina Carrer
Instituto de Investigación Médica Mercedes y Martín Ferreyra
2 shared publications - Juan Jose Lauthier
Instituto de Medicina Traslacional e Ingeniería Biomédica (IMTIB), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto Universitario del Hospital Italiano de Buenos Aires (IUHIBA), Hospital Italiano de Buenos Aires (HIBA), Buenos Aires, Argentina
2 shared publications - Laura Cecilia Laurella
CONICET—Universidad de Buenos Aires, Instituto de Química y Metabolismo del Fármaco (IQUIMEFA), Ciudad Autónoma de Buenos Aires C1113AAD, Argentina
2 shared publications - Maria Florencia Peralta
Facultad Regional Córdoba, Universidad Tecnológica Nacional, Maestro Marcelo López esq. Cruz Roja Argentina, Ciudad Universitaria, CP 5016ZAA, Córdoba, Argentina
2 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7971
Antiparasitic Activity of Sesquiterpene γ-Lactones and the Search for New Pharmaceutical Agents
This study presents a comparative in vitro evaluation of 24 natural sesquiterpene γ-lactones and selected semisynthetic derivatives against three trypanosomatid parasites responsible for neglected tropical diseases: Trypanosoma brucei brucei, Trypanosoma cruzi, and Leishmania amazonensis. The compounds were screened for antiparasitic activity across different parasite life stages, and their cytotoxicity was assessed in mammalian cells. Several compounds demonstrated high inhibitory activity (>95%) at 10 µg/mL, including estafiatin (1), grossheimin (4), cynaropicrin (5), argolide (2) derivatives, and arglabin (23). However, a marked decrease in activity was observed at lower concentrations and in intracellular parasite models, particularly for T. cruzi and L. amazonensis amastigotes. Among the tested compounds, dihydroargolide (3) and pulchellin C (19) exhibited comparatively lower cytotoxicity and were further evaluated, yielding IC50 values of 10.51 ± 1.72 µg/mL and 2.51 ± 1.13 µg/mL against T. b. brucei, respectively. Against L. amazonensis promastigotes, estafiatin (1), 8α-chloroacetoxygrossheimin (12), and arglabin (23) showed IC50 values of 0.16 ± 0.13, 0.35 ± 0.18, and 0.58 ± 0.11 µg/mL, respectively, although their selectivity indices remained limited. Comparative analysis of the dataset indicates that specific structural elements, such as the α-methylene-γ-lactone moiety and selected substituents (e.g., epoxy and acetyl groups), may influence antiparasitic activity in a species-dependent manner. At the same time, the generally low selectivity indices and reduced activity in intracellular models highlight important limitations of these compounds as direct drug leads. Overall, this work provides a systematic comparative dataset and identifies preliminary structure–activity trends that may guide further chemical optimization of sesquiterpene γ-lactones as antiparasitic hit compounds.
- 7 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7971
Open AccessAntiparasitic Activity of Sesquiterpene γ-Lactones and the Search for New Pharmaceutical Agents
This study presents a comparative in vitro evaluation of 24 natural sesquiterpene γ-lactones and selected semisynthetic derivatives against three trypanosomatid parasites responsible for neglected tropical diseases: Trypanosoma brucei brucei, Trypanosoma cruzi, and Leishmania amazonensis. The compounds were screened for antiparasitic activity across different parasite life stages, and their cytotoxicity was assessed in mammalian cells. Several compounds demonstrated high inhibitory activity (>95%) at 10 µg/mL, including estafiatin (1), grossheimin (4), cynaropicrin (5), argolide (2) derivatives, and arglabin (23). However, a marked decrease in activity was observed at lower concentrations and in intracellular parasite models, particularly for T. cruzi and L. amazonensis amastigotes. Among the tested compounds, dihydroargolide (3) and pulchellin C (19) exhibited comparatively lower cytotoxicity and were further evaluated, yielding IC50 values of 10.51 ± 1.72 µg/mL and 2.51 ± 1.13 µg/mL against T. b. brucei, respectively. Against L. amazonensis promastigotes, estafiatin (1), 8α-chloroacetoxygrossheimin (12), and arglabin (23) showed IC50 values of 0.16 ± 0.13, 0.35 ± 0.18, and 0.58 ± 0.11 µg/mL, respectively, although their selectivity indices remained limited. Comparative analysis of the dataset indicates that specific structural elements, such as the α-methylene-γ-lactone moiety and selected substituents (e.g., epoxy and acetyl groups), may influence antiparasitic activity in a species-dependent manner. At the same time, the generally low selectivity indices and reduced activity in intracellular models highlight important limitations of these compounds as direct drug leads. Overall, this work provides a systematic comparative dataset and identifies preliminary structure–activity trends that may guide further chemical optimization of sesquiterpene γ-lactones as antiparasitic hit compounds.
- Open Access
- 21 November 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (12) , 1182
Repurposing Acetylcholinesterase Inhibitors for Leishmaniasis: Donepezil Hydrochloride and Related Compounds Against the American Tegumentary Form
Background/Objective: American tegumentary leishmaniasis is a neglected tropical disease with limited therapeutic options characterized by high toxicity and poor tolerability. Drug repurpose offers a pragmatic strategy to accelerate the development of safer treatments. This study evaluated the antileishmanial activity of three clinically approved acetylcholinesterase (AChE) inhibitors—donepezil hydrochloride (DH), rivastigmine tartrate (RT), and galantamine hydrobromide (GH), tested individually and in combination with amphotericin B (AmpB) against Leishmania species relevant to tegumentary leishmaniasis. Methods: Antileishmanial activity was assessed against Leishmania (Leishmania) amazonensis promastigotes and intracellular amastigotes and Leishmania (Viannia) braziliensis promastigotes and axenic amastigotes. Cytotoxicity was evaluated in mammalian cell lines. The synergy with AmpB was analyzed at different proportions. Mechanistic studies included morphological analysis using light and scanning electron microscopy, flow cytometry, AChE activity assays, choline supplementation experiments, and membrane fluidity measurements. Results: All three AChE inhibitors demonstrated antileishmanial activity with selectivity indices > 1. DH emerged as the most promising candidate (IC50 = 16.82 μM against promastigotes; SI = 10.25), with superior potency compared to other repurposed drugs. Strong synergistic interactions with AmpB were observed for all inhibitors (χΣFIC ≤ 0.17), with DH-AmpB displaying the most robust synergy (χΣFIC = 0.09), reducing the IC 50 of AmpB by nearly 90-fold. DH induced distinct morphological alterations and acted through non-cholinergic mechanisms. The DH-AmpB combination retained maximal efficacy against L. (V.) braziliensis, with enhanced activity against clinically relevant amastigotes. Conclusions: Repurposed AChE inhibitors, particularly donepezil hydrochloride, are highly promising therapeutic candidates for tegumentary leishmaniasis. The robust synergistic effect with amphotericin B, together with their favorable safety profiles and non-antimicrobial mechanisms, positions these drugs as viable partners in dose-sparing combination regimens that could improve treatment adherence and reduce toxicity in endemic areas.
- 21 November 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (12) , 1182
Open AccessRepurposing Acetylcholinesterase Inhibitors for Leishmaniasis: Donepezil Hydrochloride and Related Compounds Against the American Tegumentary Form
Background/Objective: American tegumentary leishmaniasis is a neglected tropical disease with limited therapeutic options characterized by high toxicity and poor tolerability. Drug repurpose offers a pragmatic strategy to accelerate the development of safer treatments. This study evaluated the antileishmanial activity of three clinically approved acetylcholinesterase (AChE) inhibitors—donepezil hydrochloride (DH), rivastigmine tartrate (RT), and galantamine hydrobromide (GH), tested individually and in combination with amphotericin B (AmpB) against Leishmania species relevant to tegumentary leishmaniasis. Methods: Antileishmanial activity was assessed against Leishmania (Leishmania) amazonensis promastigotes and intracellular amastigotes and Leishmania (Viannia) braziliensis promastigotes and axenic amastigotes. Cytotoxicity was evaluated in mammalian cell lines. The synergy with AmpB was analyzed at different proportions. Mechanistic studies included morphological analysis using light and scanning electron microscopy, flow cytometry, AChE activity assays, choline supplementation experiments, and membrane fluidity measurements. Results: All three AChE inhibitors demonstrated antileishmanial activity with selectivity indices > 1. DH emerged as the most promising candidate (IC50 = 16.82 μM against promastigotes; SI = 10.25), with superior potency compared to other repurposed drugs. Strong synergistic interactions with AmpB were observed for all inhibitors (χΣFIC ≤ 0.17), with DH-AmpB displaying the most robust synergy (χΣFIC = 0.09), reducing the IC 50 of AmpB by nearly 90-fold. DH induced distinct morphological alterations and acted through non-cholinergic mechanisms. The DH-AmpB combination retained maximal efficacy against L. (V.) braziliensis, with enhanced activity against clinically relevant amastigotes. Conclusions: Repurposed AChE inhibitors, particularly donepezil hydrochloride, are highly promising therapeutic candidates for tegumentary leishmaniasis. The robust synergistic effect with amphotericin B, together with their favorable safety profiles and non-antimicrobial mechanisms, positions these drugs as viable partners in dose-sparing combination regimens that could improve treatment adherence and reduce toxicity in endemic areas.
- 3 September 2025
- Published by Springer Nature in Medical Microbiology and Immunology
- Vol. 214 (1) , 1-18
Leishmania pyruvate kinase and mitochondrial processing protease: Two novel vaccine candidates, selected via a seroproteomic approach, trigger a protective immune response against murine cutaneous leishmaniasis
- 3 September 2025
- Published by Springer Nature in Medical Microbiology and Immunology
- Vol. 214 (1) , 1-18
Leishmania pyruvate kinase and mitochondrial processing protease: Two novel vaccine candidates, selected via a seroproteomic approach, trigger a protective immune response against murine cutaneous leishmaniasis
- Open Access
- 9 June 2025
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 14 (1) , 2508766
DNA Methylation in macrophages infected with Leishmania spp. in different culture conditions
Leishmania modulate the host cell epigenome, including DNA methylation. This work aimed to explore the DNA methylation pattern in infected macrophages with L. (Viannia) braziliensis, L. (Leishmania) amazonensis and L. (L.) infantum. We performed a genome-wide methylation analysis in macrophages, cultured in presence/absence of interleukin 6 (IL-6) and infected with the three species for a period of 72hs. Upon 72hs infection, sample groups of L. (V.) braziliensis- and L. (L.) infantum-infected macrophages were treated with Glucantime and Amphotericin B for 48hs, respectively. Uninfected macrophages and macrophages treated with heat-killed Leishmania were included as controls. Several CpG islands alterations were identified upon infection and among species. The methylome analysis showed that L. (L.) amazonensis and L. (L.) infantum clustered together separately from L. (V.) braziliensis. The identified alterations were mainly associated with cytoskeleton organization. We also detected that the DNA methylation pattern of ten, six and eight CGIs for each aforementioned species slightly changed in a culture environment with IL-6, whereas treatment led to distinct DNA methylation profiles respect to untreated samples. Interestingly, some altered CGIs showed a re-establishment towards the control methylation pattern in L. (L.) infantum (69%, 11 out of 16) and L. (V.) braziliensis (36%, 4 out of 11). The identified alterations suggest a species-specific parasite/host interaction probably leading to gene expression regulation. The discovery of these methylation alterations addresses further functional studies and suggests them as potential therapeutic targets.
- 9 June 2025
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 14 (1) , 2508766
Open AccessDNA Methylation in macrophages infected with Leishmania spp. in different culture conditions
Leishmania modulate the host cell epigenome, including DNA methylation. This work aimed to explore the DNA methylation pattern in infected macrophages with L. (Viannia) braziliensis, L. (Leishmania) amazonensis and L. (L.) infantum. We performed a genome-wide methylation analysis in macrophages, cultured in presence/absence of interleukin 6 (IL-6) and infected with the three species for a period of 72hs. Upon 72hs infection, sample groups of L. (V.) braziliensis- and L. (L.) infantum-infected macrophages were treated with Glucantime and Amphotericin B for 48hs, respectively. Uninfected macrophages and macrophages treated with heat-killed Leishmania were included as controls. Several CpG islands alterations were identified upon infection and among species. The methylome analysis showed that L. (L.) amazonensis and L. (L.) infantum clustered together separately from L. (V.) braziliensis. The identified alterations were mainly associated with cytoskeleton organization. We also detected that the DNA methylation pattern of ten, six and eight CGIs for each aforementioned species slightly changed in a culture environment with IL-6, whereas treatment led to distinct DNA methylation profiles respect to untreated samples. Interestingly, some altered CGIs showed a re-establishment towards the control methylation pattern in L. (L.) infantum (69%, 11 out of 16) and L. (V.) braziliensis (36%, 4 out of 11). The identified alterations suggest a species-specific parasite/host interaction probably leading to gene expression regulation. The discovery of these methylation alterations addresses further functional studies and suggests them as potential therapeutic targets.
- Open Access
Memory T Cell Subsets Expressing Tissue Homing Receptors and Chemokine Levels in Human Tegumentary Leishmaniasis
Tegumentary leishmaniasis (TL) presents two main clinical forms: cutaneous (CL) and mucosal (ML) leishmaniasis affecting skin and nasopharyngeal mucosa. Due to parasite localization through disease stages, recruitment of T cells expressing chemokine receptors and their ligands will influence the generated host responses. The aim of this work was to characterize differential profiles of T cells expressing chemokine receptors and their plasma ligands by flow cytometry and ELISA. CL patients showed increased numbers of effector memory CD4+ T cells expressing skin homing receptors (CLA, CCR4), with the reversion of this effector phenotype observed after achieving clinical recovery. Meanwhile, ML patients showed higher frequencies of effector memory/terminal effector CD4+ and CD8+ T cells expressing chemokine receptors directed to skin (CLA, CCR4, CCR10) and mucosal (CCR6) tissues. Additionally, we reported that plasma amounts of ligands (CCL17, CCL20) vary according to the clinical form of TL. Finally, we demonstrated the ability of Leishmania spp. to modulate chemokine production (CCL17) in vitro. This work highlights the effector T cell response directed to skin and mucosal tissues in TL, emphasizing the role of cytotoxic functions in ML. The studied chemokine receptors could contribute to predicting disease progression and guiding future studies targeting relevant receptors to diminish pathogenic effector functions.
Open AccessMemory T Cell Subsets Expressing Tissue Homing Receptors and Chemokine Levels in Human Tegumentary Leishmaniasis
Tegumentary leishmaniasis (TL) presents two main clinical forms: cutaneous (CL) and mucosal (ML) leishmaniasis affecting skin and nasopharyngeal mucosa. Due to parasite localization through disease stages, recruitment of T cells expressing chemokine receptors and their ligands will influence the generated host responses. The aim of this work was to characterize differential profiles of T cells expressing chemokine receptors and their plasma ligands by flow cytometry and ELISA. CL patients showed increased numbers of effector memory CD4+ T cells expressing skin homing receptors (CLA, CCR4), with the reversion of this effector phenotype observed after achieving clinical recovery. Meanwhile, ML patients showed higher frequencies of effector memory/terminal effector CD4+ and CD8+ T cells expressing chemokine receptors directed to skin (CLA, CCR4, CCR10) and mucosal (CCR6) tissues. Additionally, we reported that plasma amounts of ligands (CCL17, CCL20) vary according to the clinical form of TL. Finally, we demonstrated the ability of Leishmania spp. to modulate chemokine production (CCL17) in vitro. This work highlights the effector T cell response directed to skin and mucosal tissues in TL, emphasizing the role of cytotoxic functions in ML. The studied chemokine receptors could contribute to predicting disease progression and guiding future studies targeting relevant receptors to diminish pathogenic effector functions.
- Open Access
Bioactive Compounds with Leishmanicidal Potential from Helianthus tuberosus and Vernonanthura squamulosa
Leishmaniasis is a neglected tropical disease caused by protozoan parasites of the genus Leishmania. An estimated 700,000 to 1 million new cases occur annually. Current therapies are limited by high toxicity, cost, prolonged treatment period, and rising resistance in endemic regions. The Asteraceae family has emerged as a promising source of bioactive compounds with proven leishmanicidal activity. In this study, the assessment of the antileishmanial activity of Helianthus tuberosus and Vernonanthura squamulosa extracts, the isolation of the sesquiterpene lactones heliangin and glaucolide A, respectively, and the evaluation of the activity of the compounds were conducted. Dichloromethane extracts of H. tuberosus and V. squamulosa were active on Leishmania amazonensis promastigotes, inhibiting the replication of the parasites in 97.2 ± 3.1% and 89.1 ± 1.1%, respectively, at 100 μg/mL. Heliangin was active against promastigotes of L. amazonensis (IC50 = 9.3 μM) and intracellular amastigotes (IC50 = 0.8 μM), while glaucolide A exhibited moderate activity against promastigotes (IC50 = 46.7 μM) and did not show activity against intracellular amastigotes. Based on these results, heliangin was further evaluated in an animal model of cutaneous leishmaniasis using BALB/c mice infected with L. amazonensis. Heliangin (8 mg/Kg), when administered in combination with Glucantime, significantly reduced lesion progression and parasite load compared to the vehicle-treated group (p < 0.001). These findings show that heliangin is a potential candidate for leishmaniasis treatment, especially in combination with therapeutic drugs.
Open AccessBioactive Compounds with Leishmanicidal Potential from Helianthus tuberosus and Vernonanthura squamulosa
Leishmaniasis is a neglected tropical disease caused by protozoan parasites of the genus Leishmania. An estimated 700,000 to 1 million new cases occur annually. Current therapies are limited by high toxicity, cost, prolonged treatment period, and rising resistance in endemic regions. The Asteraceae family has emerged as a promising source of bioactive compounds with proven leishmanicidal activity. In this study, the assessment of the antileishmanial activity of Helianthus tuberosus and Vernonanthura squamulosa extracts, the isolation of the sesquiterpene lactones heliangin and glaucolide A, respectively, and the evaluation of the activity of the compounds were conducted. Dichloromethane extracts of H. tuberosus and V. squamulosa were active on Leishmania amazonensis promastigotes, inhibiting the replication of the parasites in 97.2 ± 3.1% and 89.1 ± 1.1%, respectively, at 100 μg/mL. Heliangin was active against promastigotes of L. amazonensis (IC50 = 9.3 μM) and intracellular amastigotes (IC50 = 0.8 μM), while glaucolide A exhibited moderate activity against promastigotes (IC50 = 46.7 μM) and did not show activity against intracellular amastigotes. Based on these results, heliangin was further evaluated in an animal model of cutaneous leishmaniasis using BALB/c mice infected with L. amazonensis. Heliangin (8 mg/Kg), when administered in combination with Glucantime, significantly reduced lesion progression and parasite load compared to the vehicle-treated group (p < 0.001). These findings show that heliangin is a potential candidate for leishmaniasis treatment, especially in combination with therapeutic drugs.
- Open Access
- 8 December 2023
- Published by Andover House Inc in Precision Nanomedicine
- Vol. 6 (4) , 1179-1190
A Case of Cutaneous Leishmaniasis Cured by a Combined Treatment of Topical Miltefosine and Injectable Amphotericin B
A male rural worker with cutaneous leishmaniasis (CL) was initially treated with repeated cy-cles of Meglumine Antimoniate (Glucantime®) and two cycles of Amphotericin B deoxycholate during a three-year period. However, the patient remained with two active lesions. An experi-mental topical treatment with liposomal Miltefosine was tested. The efficacy was determined from the MD’s inspection of the patient and analysis of the lesions’ photographic images, le-sions samples culture, and anti-Leishmania antibodies quantification. The parasites from the patient were isolated. The parasites were typified as Leishmania (Viannia) braziliensis, and their susceptibility to Miltefosine, Meglumine Antimoniate, and Amphotericin B was measured. The wound healing was initially good with the topical treat-meant, but the clinical cure was achieved only with a combination of the topical liposomal Miltefosine and intravenous Amphotericin B. Of note, the treatment efficacy was strongly corre-lated with the degree of stress suffered by the patient. To our knowledge, this is the first report on using a topical Miltefosine formulation on a CL patient.
- 8 December 2023
- Published by Andover House Inc in Precision Nanomedicine
- Vol. 6 (4) , 1179-1190
Open AccessA Case of Cutaneous Leishmaniasis Cured by a Combined Treatment of Topical Miltefosine and Injectable Amphotericin B
A male rural worker with cutaneous leishmaniasis (CL) was initially treated with repeated cy-cles of Meglumine Antimoniate (Glucantime®) and two cycles of Amphotericin B deoxycholate during a three-year period. However, the patient remained with two active lesions. An experi-mental topical treatment with liposomal Miltefosine was tested. The efficacy was determined from the MD’s inspection of the patient and analysis of the lesions’ photographic images, le-sions samples culture, and anti-Leishmania antibodies quantification. The parasites from the patient were isolated. The parasites were typified as Leishmania (Viannia) braziliensis, and their susceptibility to Miltefosine, Meglumine Antimoniate, and Amphotericin B was measured. The wound healing was initially good with the topical treat-meant, but the clinical cure was achieved only with a combination of the topical liposomal Miltefosine and intravenous Amphotericin B. Of note, the treatment efficacy was strongly corre-lated with the degree of stress suffered by the patient. To our knowledge, this is the first report on using a topical Miltefosine formulation on a CL patient.